Previously doing business as Ceregen Corporation, renamed Cerecor Inc. (NASDAQ:CERC) - with facilities in Rockville, MD and in Wayne PA - having two Phase I NIH projects in its earlier days and a totally different management team, the firm has radically shifted focus since going public in 2015. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor rebranded as Avalo Therapeutics. The merger with Aevi had provided Cerecor with what was described as a clean break from companys past history with diseases of the central nervous system. Firm is now focus on developing precision medications for its core areas of focus. In addition to the break with the therapeutic focus, merger also provided the company with a new leadership team. Renamed a second time, as of August 2021 the firm is now doing business as Avalo Therapeutics indicated by the principals as better to reflect the firm's increased - and shifted - focus on immunology, immuno-oncology, and rare genetic diseases.
